| G
|
| Drug |
CYP interaction |
Clinical consequences |
| gemfibrozil (see fibrates)
| 3A4 [Clin Pharmacokinet 1998 Feb;34(2):155-62]
| Potential for interaction with 3A4 inhibitors..
|
| gestodene
| 3A4 : INHIBITS (selectively)
| ?
|
| glibenclamide { = glyburide }
| CYP3A4 : metabolism and ? inhibition
| ? interaction with e.g. fibrates,
cyclosporine
|
| glipizide
| 2C9 : METABOLISM
| low 2C9 activity causes toxicity (as for phenytoin)
|
| Glucocorticoids
| 3A4 (3A5,3A7) : INDUCED
| (See individual agents)
|
| glyburide : see glibenclamide
|
| granisetron
(granisetron does not appear to inhibit/induce any CYP)
| CYP3A4 : metabolism
| ?
|
| 1A2 (? metabolism)
| ?
|
| grapefruit juice!
| 3A4 : INHIBITS (24hr, significant)
| interacts with dihydropyridines (Ca channel blockers), terfenadine,
saquinavir, cyclosporine,
midazolam, triazolam, verapamil, diazepam; possibly
lovastatin, cisapride and astemizole
[Br J Clin Pharmacol 1998 Aug;46(2):101-10]
marked increase in diazepam bioavailability
[Eur J Drug Metab Pharmacokinet 1998 Jan-Mar;23(1):55-9]
|
| 1A2: inhibits
| ?
|
| growth hormone (GH)
| induces 3A4
| ?
|